ECTRIMS 2019
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
